CORRECTION: HC Wainwright & Co. Reiterates Buy on BiomX, Adjusts Price Target From $7 To $2
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BiomX, but adjusted the price target from $7 to $2. This adjustment reflects a significant change in the valuation of the company.
March 08, 2024 | 4:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. reaffirmed their Buy rating on BiomX but reduced the price target from $7 to $2, indicating a significant reassessment of the company's valuation.
The reduction in price target from $7 to $2 by a reputable analyst firm like HC Wainwright & Co. suggests a significant change in the perceived value and future prospects of BiomX. This could lead to a negative short-term impact on the stock price as investors adjust their expectations based on this new valuation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100